• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

L-谷氨酰胺治疗镰状细胞病:不仅仅是减少氧化还原。

L-glutamine for sickle cell disease: more than reducing redox.

机构信息

Division of Hematology and Oncology, Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.

Division of Internal Medicine, Department of Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.

出版信息

Ann Hematol. 2022 Aug;101(8):1645-1654. doi: 10.1007/s00277-022-04867-y. Epub 2022 May 14.

DOI:10.1007/s00277-022-04867-y
PMID:35568758
Abstract

Oxidative stress is a major contributor to the pathophysiology of sickle cell disease (SCD) including hemolysis and vaso-occlusive crisis (VOC). L-glutamine is a conditionally essential amino acid with important roles, including the synthesis of antioxidants, such as reduced glutathione and the cofactors NAD(H) and NADP(H), as well as nitric oxide. Given the increased levels of oxidative stress and lower (NADH):(NAD +  + NADH) ratio in sickle erythrocytes that adversely affects the blood rheology compared to normal red blood cells, L-glutamine was investigated for its therapeutic potential to reduce VOC. While L-glutamine was approved by the United States (US) Food and Drug Administration to treat SCD, its impact on the redox environment in sickle erythrocytes is not fully understood. The mechanism through which L-glutamine reduces VOC in SCD is also not clear. In this paper, we will summarize the results of the Phase 3 study that led to the approval of L-glutamine for treating SCD and discuss its assumed mechanisms of action. We will examine the role of L-glutamine in health and propose how the extra-erythrocytic functions of L-glutamine might contribute to its beneficial effects in SCD. Further research into the role of L-glutamine on extra-erythrocyte functions might help the development of an improved formulation with more efficacy.

摘要

氧化应激是导致镰状细胞病(SCD)病理生理学的主要因素,包括溶血和血管阻塞性危象(VOC)。L-谷氨酰胺是一种条件必需氨基酸,具有重要作用,包括合成抗氧化剂,如还原型谷胱甘肽以及辅酶 NAD(H)和 NADP(H),以及一氧化氮。由于镰状红细胞中氧化应激水平升高和(NADH):(NAD + + NADH)比值降低,这会影响血液流变学,与正常红细胞相比不利,因此研究了 L-谷氨酰胺治疗 VOC 的潜在治疗作用。虽然 L-谷氨酰胺已被美国(US)食品和药物管理局批准用于治疗 SCD,但它对镰状红细胞氧化还原环境的影响尚未完全清楚。L-谷氨酰胺在 SCD 中降低 VOC 的机制也不清楚。在本文中,我们将总结导致 L-谷氨酰胺批准用于治疗 SCD 的 3 期研究结果,并讨论其假定的作用机制。我们将研究 L-谷氨酰胺在健康中的作用,并提出 L-谷氨酰胺的细胞外功能如何有助于其在 SCD 中的有益作用。进一步研究 L-谷氨酰胺对细胞外功能的作用可能有助于开发更有效的改良制剂。

相似文献

1
L-glutamine for sickle cell disease: more than reducing redox.L-谷氨酰胺治疗镰状细胞病:不仅仅是减少氧化还原。
Ann Hematol. 2022 Aug;101(8):1645-1654. doi: 10.1007/s00277-022-04867-y. Epub 2022 May 14.
2
L-Glutamine in sickle cell disease.镰状细胞病中的L-谷氨酰胺。
Drugs Today (Barc). 2020 Apr;56(4):257-268. doi: 10.1358/dot.2020.56.4.3110575.
3
Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential.口服L-谷氨酰胺治疗镰状细胞贫血:I. 主观临床改善及红细胞NAD氧化还原电位的有利变化
Am J Hematol. 1998 Jun;58(2):117-21. doi: 10.1002/(sici)1096-8652(199806)58:2<117::aid-ajh5>3.0.co;2-v.
4
Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.系统性评价 l-谷氨酰胺预防镰状细胞病患者血管阻塞性疼痛危象。
Pharmacotherapy. 2019 Nov;39(11):1095-1104. doi: 10.1002/phar.2329. Epub 2019 Oct 9.
5
Endari treatment ameliorates sickle cell-related disruption in intestinal barrier functions and is associated with prolonged survival in sickle cell mice.恩达利治疗改善了镰状细胞相关的肠道屏障功能障碍,并与镰状细胞小鼠的生存延长相关。
Hematology. 2024 Dec;29(1):2331940. doi: 10.1080/16078454.2024.2331940. Epub 2024 Mar 25.
6
Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.镰状细胞病中的红细胞谷氨酰胺耗竭、氧化还原环境改变与肺动脉高压
Blood. 2008 Jan 1;111(1):402-10. doi: 10.1182/blood-2007-04-081703. Epub 2007 Sep 11.
7
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.系统性评价克里扎尼单抗:一种新的注射用药物,可减少镰状细胞病患者血管阻塞性危象疼痛发作
Pharmacotherapy. 2020 Jun;40(6):535-543. doi: 10.1002/phar.2409. Epub 2020 May 20.
8
Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.比较L-谷氨酰胺、伐地考昔和克立唑单抗在降低镰状细胞病血管闭塞性危象发生率方面的安全性和有效性:一项系统评价。
Cureus. 2022 May 11;14(5):e24920. doi: 10.7759/cureus.24920. eCollection 2022 May.
9
Real-World data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients.关于L-谷氨酰胺预防儿童和成人镰状细胞病相关并发症疗效的真实世界数据。
Front Med (Lausanne). 2022 Aug 1;9:931925. doi: 10.3389/fmed.2022.931925. eCollection 2022.
10
Safety and efficacy of L-Glutamine in reducing the frequency of acute complications among patients with sickle cell disease: A randomized controlled study.L-谷氨酰胺降低镰状细胞病患者急性并发症发生率的安全性和有效性:一项随机对照研究。
Ann Hematol. 2024 Sep;103(9):3493-3506. doi: 10.1007/s00277-024-05877-8. Epub 2024 Jul 19.

引用本文的文献

1
The histone deacetylase inhibitor CT-101 flips the switch to fetal hemoglobin expression in sickle cell disease mice.组蛋白脱乙酰酶抑制剂CT-101可使镰状细胞病小鼠体内的开关转向胎儿血红蛋白表达。
PLoS One. 2025 May 13;20(5):e0323550. doi: 10.1371/journal.pone.0323550. eCollection 2025.
2
A review on disease modifying pharmacologic therapies for sickle cell disease.镰状细胞病疾病修饰药物治疗综述
Ann Hematol. 2025 Feb;104(2):881-893. doi: 10.1007/s00277-025-06216-1. Epub 2025 Jan 20.
3
Glutamine promotes the proliferation of intestinal stem cells via inhibition of TP53-induced glycolysis and apoptosis regulator promoter methylation in burned mice.

本文引用的文献

1
Intestinal pathophysiological abnormalities in steady state and after vaso-occlusive crisis in murine sickle cell disease.稳态时和血管阻塞性危象后小鼠镰状细胞病的肠道病理生理学异常。
Br J Haematol. 2022 Feb;196(3):777-780. doi: 10.1111/bjh.17889. Epub 2021 Oct 10.
2
The gut microbiome in sickle cell disease: Characterization and potential implications.镰状细胞病中的肠道微生物组:特征与潜在影响
PLoS One. 2021 Aug 25;16(8):e0255956. doi: 10.1371/journal.pone.0255956. eCollection 2021.
3
L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality.
谷氨酰胺通过抑制TP53诱导的糖酵解和凋亡调节因子启动子甲基化促进烧伤小鼠肠道干细胞的增殖。
Burns Trauma. 2024 Sep 26;12:tkae045. doi: 10.1093/burnst/tkae045. eCollection 2024.
4
Safety and efficacy of L-Glutamine in reducing the frequency of acute complications among patients with sickle cell disease: A randomized controlled study.L-谷氨酰胺降低镰状细胞病患者急性并发症发生率的安全性和有效性:一项随机对照研究。
Ann Hematol. 2024 Sep;103(9):3493-3506. doi: 10.1007/s00277-024-05877-8. Epub 2024 Jul 19.
5
Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.作为镰状细胞病药物发现平台的预纤维状镰状血红蛋白寡聚物的荧光寿命测量。
Biomacromolecules. 2022 Sep 12;23(9):3822-3830. doi: 10.1021/acs.biomac.2c00671. Epub 2022 Aug 9.
L-谷氨酰胺在成年镰状细胞病患者中的应用:成功与现实接轨的临床试验。
Am J Hematol. 2021 Jan;96(1):E38-E40. doi: 10.1002/ajh.26021. Epub 2020 Oct 29.
4
Treating sickle cell anemia: A new era dawns.治疗镰状细胞贫血:一个新时代来临。
Am J Hematol. 2020 Apr;95(4):338-342. doi: 10.1002/ajh.25724. Epub 2020 Jan 21.
5
Rifaximin on intestinally-related pathologic changes in sickle cell disease.利福昔明对镰状细胞病肠道相关病理变化的影响
Am J Hematol. 2020 Apr;95(4):E83-E86. doi: 10.1002/ajh.25722. Epub 2020 Feb 3.
6
Rifaximin for sickle cell disease.利福昔明用于镰状细胞病。
Am J Hematol. 2019 Dec;94(12):E325-E328. doi: 10.1002/ajh.25637. Epub 2019 Oct 7.
7
Intestinal injury and gut permeability in sickle cell disease.镰状细胞病中的肠损伤和肠道通透性。
J Transl Med. 2019 May 30;17(1):183. doi: 10.1186/s12967-019-1938-8.
8
Pathophysiology of Sickle Cell Disease.镰状细胞病的病理生理学。
Annu Rev Pathol. 2019 Jan 24;14:263-292. doi: 10.1146/annurev-pathmechdis-012418-012838. Epub 2018 Oct 17.
9
Invasive non-typhoidal Salmonella in sickle cell disease in Africa: is increased gut permeability the missing link?非洲镰状细胞病中的侵袭性非伤寒沙门氏菌:肠道通透性增加是缺失的环节吗?
J Transl Med. 2018 Aug 30;16(1):239. doi: 10.1186/s12967-018-1622-4.
10
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.一项关于 l-谷氨酰胺在镰状细胞病中应用的 3 期临床试验。
N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971.